GlassScriptPhysician profile
Timithy M Dunham
NPI 1477569424
$13,231.29
in general payments reported to CMS, 2019-2025
33 companies · $2,629 in 2025
The $2,629 reported for 2025 was more than what 91% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,490 · 2020: $430 · 2021: $1,515 · 2022: $1,176 · 2023: $1,103 · 2024: $1,889 · 2025: $2,629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,620.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $2,142.66 | 2019-2023 | One Series Ultra, Tecnis Iol, Veritas Vision System |
| Biotissue Holdings INC. | $1,510.50 | 2019-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,060.62 | 2019-2021 | |
| Alcon Vision LLC | $1,036.08 | 2019-2025 | Centurion, Rocklatan, Tryptyr |
| Lensar, INC. | $890.32 | 2019-2025 | Lensar Laser System |
| Bausch & Lomb Americas INC. | $877.86 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Abbvie INC. | $546.64 | 2023-2025 | Durysta, Xen Glaucoma Treatment System |
| Mallinckrodt Hospital Products INC. | $510.45 | 2024-2025 | Acthar |
| Aerie Pharmaceuticals, INC. | $507.93 | 2019-2021 | |
| Dompe US, INC. | $365.79 | 2019-2024 | Oxervate |
| Beaver-Visitec International, INC. | $363.55 | 2021-2022 | |
| New World Medical,INC. | $315.59 | 2024 | Streamline, Clearpath, Ahmed Glaucoma Valve |
| Carl Zeiss Meditec, INC. | $306.21 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $246.05 | 2019-2022 | |
| Genentech USA, INC. | $241.62 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $235.36 | 2019 | |
| Sight Sciences, INC. | $224.60 | 2021-2025 | Omni Surgical System |
| Eyepoint US, INC. | $214.35 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $209.71 | 2019-2021 | |
| Allergan, INC. | $189.86 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $179.37 | 2019 | |
| Eyevance Pharmaceuticals LLC | $145.20 | 2019-2021 | |
| Glaukos Corporation | $140.89 | 2019 | |
| Rayner Intraocular Lenses Limited | $125.00 | 2024 | Rayone Aspheric, Rayone Spheric, Rayone Emv |
| Thea Pharma INC. | $109.08 | 2022-2025 | Iyuzeh |
| Nova Eye, INC. | $105.13 | 2025 | |
| Ocular Therapeutix, INC. | $104.43 | 2022-2024 | Dextenza |
| Tarsus Pharmaceuticals, INC. | $83.59 | 2024-2025 | Xdemvy |
| Carl Zeiss Meditec USA, INC. | $67.82 | 2022 | |
| Shire North American Group INC | $52.06 | 2019 | |
| Astellas Pharma US INC | $46.32 | 2025 | Izervay |
| Harrow Eye, LLC | $45.55 | 2025 | Triesence, Vevye |
| Oyster Point Pharma, INC. | $31.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timithy Dunham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.